Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas

Acta Neurochirurgica

Volumn 146, Issue 2, 2004, Pages 111-118

  Sirén, Vappu ^a   Antinheimo, J P ^b   Jaaskelainen J ^b   Bohling T ^a   Carpen O ^a   Vaheri, A ^a   Kilic, T ^c   De Tribolet, N ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NONE

Author keywords

NF2; PAI 1; Schwannoma; TPA; UPA; UPAR

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEURILEMOMA; NEUROFIBROMATOSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITATIVE ANALYSIS; SCHWANN CELL; SURAL NERVE; TUMOR CELL;

EID: 1542351150     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00701-003-0183-2     Document Type: Article

References (32)

1. Akassoglou K, Kombrinck KW, Degen JL, Strickland S (2000) Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 149: 1157-1166
2. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K (1986) Plasminogen activator inhibitor type 1: reactive center and aminoterminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 209: 213-218
3. Antinheimo A, Haapasalo H, Seppälä M, Sainio M, Carpén O, Jääskeläinen J (1995) Proliferative potential of sporadic and neurofibromatosis 2-associated Schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 54: 776-782
4. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J (2000) Population-based analysis of sporadic and NF2-associated meningeomas and schwannomas. Neurology 54: 71-76
5. Arai Y, Kubota T, Nakagawa M, Kabuto M, Kobayashi H (1998) Production of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human brain tumors. Acta Neurochir (Wien) 140: 377-386
6. Bindal AK, Hammoud R, Shi WM, Wu SZ, Sawaya R, Rao JS (1994) Prognostic significance of proteolytic enzymes in human brain tumors. J Neuro-Onc 22: 101-110
7. Clark MB, Zeheb R, White TK, Bunge RP (1991) Schwann cell plasminogen activator is regulated by neurons. GLIA 4: 514-528
8. Collen D (1979) On the regulation of fibrinolysis. Thrombos Haemostas 43: 77-89
9. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266
10. Declerk PJ, De Mal M, Alessi M-C, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263: 15454-15461
11. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51-57
12. Hayden SM, Seeds NW (1996) Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia. J Neurosci 16: 2307-2317
13. Jääskeläinen J, Paetau A, Pyykkö I, Blomstedt G, Palva T, Troupp H (1994) Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg 80: 541-547
14. Kalderon N (1984) Schwann cell proliferation and local proteolysis: Expression of plasminogen-activator activity predominates in the proliferating cell populations. Proc Natl Acad Sci USA 81: 7216-7220
15. Kalderon N (1990) Glial plasminogen activators in developing and regenerating neural tissue. In: Festoff BW (ed) Serine proteases and their serpin inhibitors in the nervous system. Plenum, New York, pp 209-217
16. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823
17. Kono S, Rao JS, Bruner JM, Sawaya R (1994) Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 53: 256-262
18. Landau BJ, Kwaan HC, Verrusio EN, Brem SS (1994) Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 54: 1105-1108
19. Louis DN, Ramesh V, Gusella JF (1995) Neuropathology and molecular genetics of Neurofibromatosis 2 and related tumors. Brain Pathol 5: 163-172
20. Mimuro J, Loskutoff DJ (1989) Purification of a protein from bovine plasma that binds to type plasminogen activator inhibitor 1 and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem 264: 936-939
21. Pöllänen J, Stephens RW, Vaheri A (1991) Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273-328
22. Rogister B, Delree P, Leprince P, Martin D, Sadzot C, Malgrange B, Munaut C, Rigo JM, Lefebyre PP, Octave JN (1993) Transforming growth factor beta as a neuronoglial signal during peripheral nervous system response to injury. J Neurosci Res 34: 32-43
23. Rouleau GA, Merel P, Lutchman M, Sanson M, Zuchman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumaski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G (1993) Alternation in new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 363: 515-521
24. Salonen EM, Vaheri A, Pöllänen J, Stephens RW, Andreasen PA, Mayer M, Danø K, Gailit J, Ruoslahti E (1989) Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264:6339-6343
25. Sawaya R, Rämö J, Shi ML, Mandybur G (1991) Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74: 480-486
26. Sawaya R, Yamamoto M, Rämö OJ, Shi ML, Rayford A, Rao JS (1995) Plasminogen activator inhibitor-1 in brain tumors: Relation to malignancy and necrosis. Neurosurgery 36: 375-381
27. Sobel RA, Wang Y (1993) Vestibular (acoustic) Schwannomas: Histologic features in neurofibromatosis 2 and unilateral cases. J Neuropathol Exp Neurol 52: 106-113
28. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VM, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short PM, Buckler AJ, Gusella JF (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800
29. Vaheri A, Carpén O, Heiska L, Helander TS, Jääskelä inen J, Majander-Nordenswan P, Sainio M, Timonen T, Turunen O (1997) The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol 9: 659-666
30. Verde P, Stoppelli MP, Galeffi P, Di Nocera P, Blasi F (1984) Identification and primary sequence of an unspliced human urokinase poly(A) + RNA. Proc Natl Acad Sci USA 81: 4727-4731
31. Werb Z (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442
32. Woodruff JM, Kourea HP, Louis DN (1997) Schwannoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon, pp 126-128